T. C. Erciyes üNİversitesi eczacilik faküLtesi antidepresan biLEŞİkler hazırlayan

Wójcikowski J, Haduch A, Daniel WA. Effect of antidepressant drugs on cytochrome P450 2C11 (CYP2C11) in rat liver. 2013; 65(5): 1247-55.

Valentino R, Commons K. Peptides that fine-tune the serotonin system. Neuropeptides, Volume 39, Issue 1, Pages 1-8, February 2005.

Örsel S. Depresyonda Tedavi: Genel İlkeler ve Kullanılan Antidepresan İlaçlar. Klinik Psikiyatri 2004; Ek 4: 21.

Pollock GB. Psychopharmacology: General principles. Kaplan and Sadock's Comprehensive Textbook of Psychiatry, BJ Sadock, V Sadock (Ed), 7. Baskı, Philadelphia, Lippincott Williams and Wilkins 2000; s. 3086-3090.

Bazire S (2003) Psychotropic Drug Directory 2003/2004. Fivepin Publishing, Bath.

Yüksel N. Psikotrop İlaç Etkileşmeleri. Psikofarmakoloji. Ankara, Çizgi Tıp Yayınevi 2003; s. 521-629.

Tumer N, Scarpace PJ, Lowenthal D. Geriatric Psychopharmacology: Basic and clinical considerations. Ann Rev Pharmacol Toxicol 1992; 32: 271-302.

Örsel S, Doğruer Z. Yaşlılıkta İlaç Etkileşimleri. Psikiyatri, Psikoloji ve Psikofarmakoloji Dergisi 2001; 9: 263-270.

Mika J, Zychowska M, Makuch W, Rojewska E, Przewlocka B. Neuronal and immunological basis of action of antidepressant in chronic pain – clinical and experimental studies.  2013; 65(6): 1611-21.

Süzer Ö. Cerrahpaşa Tıp Fakültesi Farmakoloji ve Klinik Farmakoloji Anabilim Dalı, Antidepresan ve Antimanik İlaçlar, İstanbul, 2009; 8.

Örsel S. Depresyonda Tedavi: Genel İlkeler ve Kullanılan Antidepresan İlaçlar. Klinik Psikiyatri 2004; Ek 4: 19.

Süzer Ö. Cerrahpaşa Tıp Fakültesi Farmakoloji ve Klinik Farmakoloji Anabilim Dalı, Antidepresan ve Antimanik İlaçlar, İstanbul, 2009; 11.

Uzbay T, Yüksel N. Anksiyete Tedavisinde Kullanılan İlaçların Farmakolojisi ve Kullanım Güvenliği. Klinik Psikiyatri 2002; Ek 1: 22.

Santana NO,  Góis AF. Rhabdomyolysis as a manifestation of clomipramine poisoning. Sao Paulo Med J, 2013; 131(6): 432-5. Doi: 10.1590/1516-3180.2013.1316541.

Glassman AH, Bigger JT. Cardiovascular Effects of Therapeutic Doses of Tricyclic Antidepressants. Arch Gen Psychiatry, 1981; 38(7): 815-820. Doi:10.1001/archpsyc.1981.01780320095011.

Spiker DG, Weiss AN, Chang SS, Ruwitch JF Jr, Biggs JT. Clinical Pharmacology and Therapeutics [1975, 18(5 Pt 1): 539-546].

Özcankaya R, Acar A. The comparison of amitryptilline and mirtazapine side effects on depression treatment. 2001; 11(1): 17-27.

Otal Y, Karataş AD, Baydın A, Eden A.O. Ölümcül Doz Amitriptilin Zehirlenmesi: Olgu Sunumu. Fırat Tıp Dergisi 2009; 14(2): 160-162.

Öner N, Vatansever Ü, Turan Ç, Okutan Ö, Şimşek A, Duran R, Karasalihoğlu S. A Commen Intoxication In Childhood: Amitriptyline Intoxications. Turkiye Klinikleri J Pediatr 2004; 13(3): 123-8.

Mirsal H, Kalyoncu A, Pektaş O. Ecchymosis associated with the use of fluoxetine: case report. Turk Psikiyatri Derg 2002 Winter; 13(4): 320-4.

Hulten BA, Adams R, Askenasi R. Predicting severity of tricyclic antidepressant overdose. Clin Toxicol 1992; 30: 161-170.

Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993; 54: 289-299.

Sandeman DJ, Alahakoon TI, Bentley SC. Tricyclic poisoning: successful management of ventricular fibrillation following massive overdose of imipramine. Anaesth Intensive Care 1997; 25: 542-545.

Riederer P, Danielczyk W, Grünblatt E. Monoamine oxidase-B inhibition in Alzheimer’s disease. 2004 Jan; 25(1-2): 271-7.

Bocksberger JP, Gachoud JP, Richard J ve ark. Comparison of the effects of moclobemide and fluvoxamine in elderly patients with a severe depressive episode. Eur J Psychiatry 1993; 8: 319-324.

Altamura AC, Aguglia E. Moclobemide vs fluoxetine in elderly outpatients with major depression or dysthimia: a double blind trial. Eur J Psychiatry J. 1994; 1635.

Himmelhoch JM, Thase ME, Mallinger AG ve ark: Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910-916.

Mallinger AG, Edwards DJ, Himmelhoch JM ve ark: Pharmacokinetics of tranylcypromine in patients who are depressed: relationship to cardiovascular effects. Clin Pharmacol Ther 1986; 40: 444-450.

Thase ME, Himmelhoch JM, Mallinger AG. Tranylcypromine vs. imipramine in anergic bipolar depression. Abstract of paper presente at the 43rd annual meeting of the Society For Biological Psychiatry, 1988.

Vahip S. Araştırmalardan Klinik Uygulamaya Bipolar Depresyon Tedavisi. Klinik Psikofarmokoloji Bülteni 1999; 9: 213-221.

Kitaichi Y, Inoue T, Mitsui N, Nakagawa S, Kameyama R, Hayashishita Y, Shiga T, Kusumi I, Koyama T. Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report. 2013; 9: 1591-4.

Tural Ü, Önder E. Depresif Bozuklukların Tedavisinde Moklobemid Kullanımı. Klinik psikiyatri 2001; Ek 4: 12-16.

Wu ML, Deng JF. Fatal serotonin toxicity caused by moclobemide and fluoxetine overdose. 2011 Nov-Dec; 34(6): 644-9.

Sun LM, Lin MC, Liang JA, Chang YJ, Chang SN, Sung FC, Muo CH, Kao CH. Pharmacoepidemiol Drug Saf. 2013 Dec; 22(12): 1292-7. Doi: 10. 1002/pds.3523. Epub 2013 Sep 20.

Eker E, Noyan A. Yaşlıda Depresyon ve Tedavisi. Klinik Psikiyatri 2004; Ek 2: 81.

Can A, Schulze TG, Gould TD. Molecular actions and clinical pharmacogenetics of lithium therapy. 2014 Feb 15.

Thase ME, Howland RH, Friedman ES. Treating antidepressant nonresponders with augmentation strategies: An overview. J Clin Psychiatry 1998; 59 (Suppl 5): 5-12.

Arana GW, Rosenbaum JF (2000). Handbook of Psychiatric Drug Therapy. 4. Baskı, Philadelphia, Lippincott Williams&Wilkins.

Rouillon F, Gorwood P. The use of lithium to augment antidepressant medication. J Clin Psychiatry 1998; 59(Suppl 5): 32-39.

Dording CM. Antidepressant augmentation and combinations. Psychiatr Clin North Am 2000; 23: 743-755.

Thase ME, Howland RH, Friedman ES. Treating antidepressant nonresponders with augmentation strategies: An overview. J Clin Psychiatry 1998; 59(Suppl 5): 5-12.

Bauer M, Bschor T, Kunz D et al. Double-blind, placebo- controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 2000;157: 1429-1435.

Schweitzer I, Tuckwell V. Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression. Drug Saf 1998; 19(6): 455-464.

Bayraktar E, Saygılı R. Depresyonun Biyokimyası. Depresyon Monografları Serisi 4, Hekimler Yayın Birliği, 1993; s. 157-174.

Kırlı S (2000). Depresyonun Biyolojik Oluşumu ve Farmakolojik Tedavisi, Roche, Bursa.

Heninger GR, Chamey DS, Stemberg DE. Serotonergic function in depression. Arch Gen Psychiatry 1984; 41: 398-402.

Kırlı S (2002). Duygu Durumunun Düzenlenmesi ve ‘Sinaptik Homeostaziste’ Etkili olan Mekanizmalar. Depresyon, Bursa.

Ceylan ME, Oral ET. Duygudurum bozuklukları, Araştırma ve Klinik Uygulamada Biyolojik Psikiyatri. 4.Cilt, Birinci Baskı, İstanbul 2001; s.72-135.

Maes M, Meltzer HY (2000). The serotonin hypothesis of major depression, Psychopharmacology: The Fourth Generation of Progress online. FE Bloom, D Kupfer (Ed), available at: http://www.acnp.org/G4/GN401000094/ch092.html

Heninger GR (2000) Indoleamines: The role of serotonin in clinical disorders, Psychopharmacology: The Fourth Generation of Progress online. FE Bloom, D Kupfer (Ed), available at: http://www.acnp.org/G4/GN401000045/ch.html.

Andrade C. Selective serotonin reuptake inhibitor drug interactions in patients receiving statins. J Clin Psychiatr. 2014 Feb; 7 5(2): e95-9. doi: 10.4088/JCP. 13f08941.

Hariri A, Ceylan M. Depresyonda İlaç Tedavisi: Özgül Serotonin Gerialım Engelleyicileri Duygudurum Dizisi. 2003; 7: 341.

Akbulut S, Yagmur Y, Gumus S, Babur M. Breast ecchymosis: Unusual complication of an antidepressant agent. Int J Surg Case Rep. 2014;5(3):129-30. doi: 10.1016/j.ijscr.2014.01.004. Epub 2014 Jan 16.

Mirsal H, Kalyoncu A, Pektaş O. Ecchymosis associated with the use of fluoxetine: case report. Turk Psikiyatri Derg 2002 Winter; 13(4): 320-4.

Gülseren L, Gülseren Ş, Hekimsoy Z, Bodur Z, Kültür Ş. Major depresif bozukluğu olan diabete mellituslu hastalarda fluoksetin ve paroksetinin depresyon-anksiyete ve yaşama kalitesi, yeti yitimi ve metabolik kontrol üzerine etkisi: Tek kör, karşılaştırmalı bir çalışma. 2001; 11(1): 1-10.

Halikay JA. Org. 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol. 1995; 10(Suppl 2): 25-133.

Atmaca M, Kuloğlu M, Geçici Ö, Ünal A, Firidin B, Tezcan AE. The comparison of efficacy and safety of nefazodone and amitriptyline in the treatment of major depressive disorder. Bulletin of Clinical Psychopharmacology 2001; 11(3): 160-167.

74. Bourin M. Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review, Human Psychopharmacology: Clinical and Experimental Volume 18, Issue 3, pages 185–190, April 2003.

75. 
    Uguz F, Sahingoz M, Kose S, Ozbebit O, Sengul C, Selvi Y, Sengul C, Ayhan M, Dagistanli A, Askin R. Antidepressants and menstruation disorders in women: a cross-sectional study in three centers. General Hospital Psychiatry Volume 34, Issue 5, September–October 2012, Pages 529–533.
    
76. 
    Hariri A, Ceylan M. Depresyonda İlaç Tedavisi: Özgül Serotonin Gerialım Engelleyicileri, Duygudurum Dizisi.
    
77. 
    Sayın A. Paroksetinin Sosyal Anksiyete Bozukluğu Tedavisinde Kullanımı, Klinik Psikiyatri 2007; 10(Ek 2): 11-15.
    
78. 
    Stein MB, Liebowitz MR, Lydiard RB ve ark. Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial. JAMA 1998; 280: 708-713.
    
79. 
    Kocer M, Zincir S, Yukselir C, Ak M. Paroxetine Induced Thrombocytopenia: A Case Report. Bulletin of Clinical Psychopharmacology 2012; 22(Suppl. 1): S123
    
80. 
    Tomruk N, Oral T. Elektrokonvulsif tedavinin klinik kullanımı: Bir gözden geçirme. Anadolu Psikiyatri Dergisi 2007; 8: 302-309.
    
81. 
    McCall WV. Electroconvulsive therapy in the era of modern psychopharmacology. Int J Neuropsychopharmacol 2001; 4: 315-324.
    
82. 
    Mayor S. ECT may be better than drugs for short term depression. BMJ 2003; 326 (7389): 569.
    
83. 
    Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr. Principles and Practice of Psychopharmacotherapy, second ed. Baltimore, Williams & Wilkins, 1997; 373-374.
    
84. 
    The UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003; 361: 799-808.
    
85. 
    National Institute of Mental Health. NIMH Consensus Statement on Electroconvulsive Therapy 1985; 5: 1-23.
    
86. 
    Philbert RA, Richards L, Lynch CF, Winokur G. Effect of ECT on mortality and clinical outcome in geriatric unipolar depression. J Clin Psychiatry 1995; 56: 390-394.
    
87. 
    O'Leary DA, Lee AS. Seven year prognosis in depression: mortality and readmission risk in the Nottingham ECT cohort. Br J Psychiatry 1996; 169: 423-429.
    
88. 
    National Institute of Mental Health. NIMH Consensus Statement on Electroconvulsive Therapy 1985; 5: 1-23.
    
89. 
    American Psychiatric Association Task Force on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy, second ed, Washington, DC, American Psychiatric Press, 2001.
    
90. 
    The Consensus Group Affiliated to the Special Committee. The place of ECT in contemporary psychiatric practice. AIF Scott (ed), The ECT Handbook-The Third Report of the Royal College of Psychiatrists' Special Committee on ECT. London, Royal College of Psychiatrists, 2005; p. 3-8.
    
91. 
    Whitehouse AM. The use of ECT in the treatment of mania. AIF Scott, The ECT Handbook -Report of the Royal College of Psychiatrists' Special Committee on ECT, London, Royal College of Psychiatrists, 2005; p.25-29.
    

Ö

ZGEÇMİŞ

Hatice TORAMAN, 1991 yılında Sivas’ta doğdu. İlk öğrenimini İstiklal İlköğretim Okulu, orta öğrenimini Behrampaşa İlköretim Okulu’nda, liseyi Selçuk Anadolu Lisesi’nde tamamladıktan sonra 2009 yılında girdiği Erciyes Üniversitesi Eczacılık Fakültesi’nden 2014 yılında mezun oldu.

İletişim Bilgileri

E-mail: [e-mail]